12.1 Bronchial Provocation Studies

Bronchial Provocation on the RPFT Blueprint

Domain II of the NBRC PFT Detailed Content Outline places bronchial provocation under special procedures: select the study (II.A.15.b), perform it (II.B.15.b), and evaluate validity of the result (II.C.15.b). These items test whether you know when a challenge is indicated, which agent fits the clinical question, how to step doses safely, how to calculate PC20/PD20, and when to stop or reject a run.

Airway hyperresponsiveness (AHR) is an exaggerated bronchoconstrictor response to a stimulus that would produce little change in a healthy airway. Spirometry alone may be normal between attacks. Provocation testing provides objective evidence of AHR to support (or argue against) an asthma diagnosis, occupational airway disease workup, or evaluation of exercise-related symptoms.

Indications

Select bronchial provocation when the order and clinical context fit one or more of the following:

Provocation is not a first-line substitute for a carefully performed baseline spirometry and, when appropriate, bronchodilator response study. If baseline FEV1 already shows clear obstruction with a large bronchodilator response, the diagnosis may already be supported without a challenge—selection (II.A.15.b) means choosing the right next test, not stacking redundant risk.

Agents and Stimulus Classes

Direct vs indirect challenges

Methacholine is the classic stepwise aerosol challenge used in many PFT laboratories. Mannitol is an indirect dry-powder osmotic challenge with its own stepwise protocol and approved product labeling. Exercise testing for EIB uses a controlled exercise bout followed by serial post-exercise spirometry. EVH requires the patient to hyperventilate dry gas enriched with CO₂ (typically ~5% CO₂ to maintain eucapnia) at a high target minute ventilation for a defined period, then serial FEV1 measurements—used especially in athletes and EIB evaluation when available.

Choosing among agents (II.A.15.b)

• Methacholine: widely available pharmacologic AHR test when asthma is suspected and spirometry is nondiagnostic; standardized concentration/dose steps.
• Mannitol / indirect: preferred when the clinical question emphasizes airway inflammation–related responsiveness or when protocol/specialist request specifies indirect challenge.
• Exercise or EVH: preferred when symptoms are exercise-triggered or for sports/military-style EIB documentation; requires appropriate monitoring and recovery pathways.
• Do not improvise agent switches mid-protocol without a new order and SOP; agent, doses, and stopping rules are protocol-specific.

Contraindications and Pre-Test Screening

Absolute and relative contraindications exist because intentional bronchoconstriction can worsen gas exchange, cardiac stress, and symptoms. Screen before dosing:

Withhold or reschedule rather than “try one dose and see” when a hard contraindication is present. Document medications that blunt AHR (e.g., recent short- and long-acting bronchodilators, some antihistamines, leukotriene modifiers—timing per protocol) so a false-negative challenge is not misread as “no asthma.”

Protocol Concepts: Doubling Doses, PC20/PD20, Stopping Rules

Methacholine structure (conceptual)

1. Confirm pre-test spirometry meets quality criteria; record baseline FEV1.
2. Deliver diluent (control) if protocol requires; remeasure FEV1.
3. Administer increasing methacholine concentrations, classically in doubling steps (some protocols use quadrupling for efficiency under defined rules).
4. After each dose, measure FEV1 at protocol-timed intervals (often ~30–90 seconds and again within a few minutes—know that timing is standardized, not random).
5. Continue until a ≥ 20% fall in FEV1 from the reference baseline (post-diluent or pre-challenge per protocol) or the highest concentration is reached or a safety stopping rule is met.

PC20 and PD20

• PC20: Provocative concentration of methacholine causing a 20% decrease in FEV1 (typically reported in mg/mL).
• PD20: Provocative dose causing a 20% FEV1 fall (cumulative dose units—protocol/device specific).

A lower PC20/PD20 means greater hyperresponsiveness (less agent needed to drop FEV1 20%). Interpretation cut-points (normal vs borderline vs mild/moderate/severe AHR) are standard- and lab-defined; the RPFT must calculate or recognize the endpoint concept and report it correctly, not invent clinical labels without the reference table.

Worked conceptual example

Baseline (post-diluent) FEV1 = 3.00 L. After a given concentration step, best acceptable FEV1 = 2.34 L.

Percent fall = (3.00 − 2.34) / 3.00 × 100% = 22%

The ≥ 20% threshold is met at that concentration. If the fall crossed 20% between two steps, software/lab calculation interpolates PC20 between the last concentration below 20% fall and the first at or above 20% fall. Exam stems may give two points and ask which value is the PC20-related concentration or whether the test is positive.

Stopping rules and recovery

Stop dosing when:

• FEV1 falls ≥ 20% (positive challenge endpoint for that protocol), or
• Maximum concentration/dose completed without 20% fall (negative or nonresponsive within the range tested), or
• Patient develops significant distress, SpO2 desaturation beyond policy, chest pain, near-syncope, or other adverse events, or
• Spirometry becomes unacceptable and cannot be restored with coaching

Recovery: administer a rapid-acting bronchodilator (typically inhaled short-acting β-agonist) after a positive test or significant fall, and remeasure FEV1 until it returns toward baseline (often within ~10–15% of baseline or per SOP). Never discharge a still-severely constricted patient without documented recovery and clinical stability. Keep emergency equipment and trained personnel available for the entire challenge (patient safety carries from Domain II safety content).

Safety Monitoring

Throughout provocation (II.B.15.b performance):

• Continuous or frequent SpO2 per protocol
• Symptom scoring (chest tightness, wheeze, cough, dyspnea, lightheadedness)
• Observation for audible wheeze, accessory muscle use, distress
• Immediate access to bronchodilator, oxygen, and emergency response pathway
• Abort criteria pre-briefed to the patient: they may stop; you will stop for safety even if they want to “push through”

Exercise and EVH add cardiorespiratory monitoring appropriate to the lab’s exercise/EIB SOP (heart rate targets, ECG if required by order/policy, thermal/environmental control of inspired air).

Performing and Validating the Study (II.B.15.b / II.C.15.b)

Performance checklist concepts: correct agent preparation and delivery device; dose/concentration verification; tight mouthpiece/nose clip for spirometry; acceptable FEV1 efforts after each step; accurate timing; clear documentation of each FEV1 and percent change; bronchodilator recovery; incident reporting if adverse events occur.

Validity (II.C.15.b): reject or qualify results when baseline spirometry was unacceptable, doses were mis-sequenced, FEV1 efforts after doses fail acceptability/repeatability, the patient discontinued for non-protocol reasons without a defined endpoint, recovery was not documented after a large fall, or medications/withhold failures make a negative test uninterpretable. A “negative” challenge after recent LABA use may be false negative—flag it rather than report as definitive absence of AHR.

Clinical Scenario

A 28-year-old with episodic nocturnal cough and normal baseline spirometry (FEV1 98% predicted, no BD response) is ordered for methacholine challenge. Pre-test screen: BP controlled, no recent MI, FEV1 well above low-FEV1 cutoffs, can perform grade-A spirometry. You select methacholine per order (II.A.15.b), perform doubling concentrations with post-dose FEV1, achieve a 23% fall at a mid-range concentration, compute PC20, give albuterol, and document FEV1 recovery to within 5% of baseline (II.B.15.b). Validity review confirms acceptable efforts at each step and correct withhold of bronchodilators (II.C.15.b).

Link to Practice

/practice/rpftPractice questions with detailed explanations